One company has recently innovated a new line of chewable leveraging its technology platform capable of encapsulating and stably maintaining a wide range of liquid and solid active ingredients.
FREMONT, CA: The solid oral dose can be the cornerstone of hospitals, but new advances in medication delivery products make it possible for consumers and pharmaceutical firms to use substitutes. Tablets and gel capsules are lightweight and easy for packaging and travel, but many users have trouble swallowing pills.
Here is a look at how developments for injectables and chewables are changing the pharma of drug delivery choices.
Since the gummies entered the scene, their smooth chewable texture has given a more enjoyable patient experience. Gummies or chewable gels have significant disadvantages, such as low thermostability, which leads to the shorter shelf life of the substance and lack of active content during the production process. This lack of standardized consistency and the expense of scaling up a modern production method is part of the sluggish introduction of soft chewable prescription dosage types.
To overcome these issues, one company has recently innovated a new line of chewable leveraging its technology platform capable of encapsulating and stably maintaining a wide range of liquid and solid active ingredients. According to the firm, the chewables are created by forming a complexation of polymers strengthened by chemical crosslinking and may involve different API layers with separate release profiles. These chewables have a low cost of production and increased stability. Their texture and consistency are intended to be organoleptically pleasing for enhanced patient adherence while maintaining child safety risks.
Getting the little information right for the drug delivery will make a significant difference when delivering medicines to the market fast. With the steady growth in FDA approvals, continued generic competition, and global price pressures, the market pace is becoming increasingly necessary for producers who need to produce different products in their portfolios rapidly. A single entity-component software has been designed to offer a stable, reliable component framework that is compliant with a wide range of generic drug molecules and chemicals to address this requirement. The program allows generic drug makers to provide delivery solutions and packaging for a range of molecules using a single formula platform.